10:38 AM EDT, 08/07/2024 (MT Newswires) -- MoonLake Immunotherapeutics ( MLTX ) shares were slightly up in recent Wednesday trading despite posting a wider Q2 net loss from a year earlier.

The biotechnology company reported a Q2 loss of $0.39 per share, widening from a loss of $0.23 a year earlier.

Analysts polled by Capital IQ expected a loss of $0.29.

As expected, no revenue for the quarter ended June 30 was reported.

As of June 30, MoonLake said it had $519.8 million in cash, cash equivalents and short-term marketable securities, and expected it could fund operating expenses and capital expenditure requirements until the end of 2026.

Price: 44.20, Change: +0.27, Percent Change: +0.61